ArticleDiabetology & metabolic syndrome2025
LncRNA NBR2 affects pancreatic β-cell function in type 2 diabetes mellitus by targeting miR-646.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is one of the major diseases threatening human health. This study aims to investigate the role of the NBR2/miR-646 axis in T2DM and pancreatic β-cell function.
methods95 T2DM patients and 83 healthy individuals were enrolled in the study. Serum NBR2 and miR-646 expression were detected by quantitative reverse transcription polymerase chain reaction. The diagnostic value of NBR2 in T2DM was evaluated using receiver operating characteristic curve. To assess cell viability and apoptosis, the cell counting kit-8 assay and flow cytometry were utilized. Enzyme-linked immunosorbent assay was employed to determine insulin secretion, levels of inflammatory factors, and oxidative stress. The interaction between NBR2 and its target was confirmed using luciferase reporter assay, and their association was evaluated through Pearson correlation analysis.
resultsSerum NBR2 expression was upregulated in T2DM patients, while miR-646 expression was decreased. NBR2 could serve as a biomarker for T2DM diagnosis, with an area under the curve of 0.908 (95% confidence interval : 0.866-0.950), sensitivity of 89.5%, and specificity of 79.5%, and was negatively correlated with miR-646. Inhibiting NBR2 could increase the viability of INS-1 cells, insulin secretion, and superoxide dismutase activity, while reducing apoptosis, as well as the levels of interleukin-6, tumor necrosis factor-α, and malondialdehyde. miR-646 was identified as a target of NBR2. Inhibiting miR-646 could partially reverse the protective effect of NBR2 inhibition on cell function damage.
conclusionNBR2 is highly expressed in T2DM patients and has potential value in T2DM diagnosis. NBR2 can participate in the regulation of pancreatic β-cell function by modulating miR-646.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.